Novel Markers And Therapies For Patients With Acute Heart Failure And Renal Dysfunction: A Systematic Review.
Am J Med. 2014 Nov 13;
Authors: McCullough PA, Jefferies JL
BACKGROUND: Acute kidney injury complicates decompensated heart failure in ∼33% of cases and is associated with morbidity and mortality, thus, we sought to systematically review this topic in order to summarize novel diagnostic and therapeutic approaches.
METHODS: Structured PubMed searches on these topics were conducted in February 2014 and relevant literature was identified. The PubMed search identified a total of 192 articles that were individually screened for inclusion in this analysis and 58 were included.
RESULTS: Acute kidney injury, defined by substantial rises in serum creatinine, is consistently associated with prolonged length of stay, rehospitalization, and mortality. Biomarker studies suggested that natriuretic peptides are prognostic for shorter and longer term mortality. Novel proteins indicating kidney damage and albumin in the urine are associated with acute kidney injury. The most promising acute pharmacologic treatment appears to be serelaxin, which has been shown to improve acute heart failure symptoms, hemodynamic parameters, and renal function.
CONCLUSIONS: The presence of acute kidney injury results in worse clinical outcomes for patients with acute heart failure. Novel biomarkers and therapies hold the promise of improving both cardiac and renal outcomes in these patients.
PMID: 25446297 [PubMed - as supplied by publisher]